AGILE

Michael J. Graff of Air Liquide Announced as Vice Chair of AIChE Foundation

Retrieved on: 
Tuesday, February 27, 2024

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The American Institute of Chemical Engineers (AIChE®) has announced the selection of Michael (Mike) J. Graff, Chairman and CEO of American Air Liquide Inc., and Executive Vice President of Air Liquide Group, as Vice Chair of the AIChE Foundation Board of Trustees.

Key Points: 
  • NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The American Institute of Chemical Engineers (AIChE®) has announced the selection of Michael (Mike) J. Graff, Chairman and CEO of American Air Liquide Inc., and Executive Vice President of Air Liquide Group, as Vice Chair of the AIChE Foundation Board of Trustees.
  • Graff joins a team led by Jennifer Sinclair Curtis, Distinguished Professor of Chemical Engineering at the University of California, Davis.
  • Graff began his term as Vice Chair in January 2024, and he will succeed Curtis as Foundation Chair in 2026.
  • For more information about the AIChE Foundation and its projects, visit www.aiche.org/giving.

Reliable Robotics Demonstrates Flexibility of Autonomous Flight System in an Operational Mission for the U.S. Air Force

Retrieved on: 
Wednesday, February 14, 2024

In conjunction with the Air Combat Command branch of the U.S. Air Force's AGILE FLAG exercise, Reliable demonstrated its autonomous flight system for intra-theater military logistics.

Key Points: 
  • In conjunction with the Air Combat Command branch of the U.S. Air Force's AGILE FLAG exercise, Reliable demonstrated its autonomous flight system for intra-theater military logistics.
  • Reliable’s autonomous flight system includes an “always on” autopilot which handles all phases of aircraft operation including autotaxi, autotakeoff, autoflight and autoland.
  • View the full release here: https://www.businesswire.com/news/home/20240214333635/en/
    Reliable Robotics remotely operates a flight 120 miles away using a portable control station.
  • With the only FAA-approved autonomous aircraft certification plan for full aircraft automation, Reliable has the most advanced certification program for an autonomous flight system.

Global Coalition for Adaptive Research in Collaboration with Cure Brain Cancer Foundation Announce the Opening of Glioblastoma Clinical Trial in Australia

Retrieved on: 
Tuesday, November 14, 2023

The Global Coalition for Adaptive Research (GCAR) in collaboration with Cure Brain Cancer Foundation (CBCF), today announced the opening of GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447) in Australia.

Key Points: 
  • The Global Coalition for Adaptive Research (GCAR) in collaboration with Cure Brain Cancer Foundation (CBCF), today announced the opening of GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447) in Australia.
  • GBM AGILE is a revolutionary patient-centered, adaptive platform trial for registration that evaluates multiple therapies for patients with newly-diagnosed and recurrent glioblastoma (GBM) – the deadliest form of brain cancer.
  • “Cure Brain Cancer Foundation is an organization dedicated to rapidly improving brain cancer survival and ultimately finding a cure.
  • We are thrilled that patients in Australia will be able to participate in this innovative clinical trial,” said Lance Kawaguchi, CEO, Cure Brain Cancer Foundation.

2024 AGILE Conference Announces Keynote Speaker, Session Topics

Retrieved on: 
Tuesday, November 14, 2023

DALLAS, Nov. 14, 2023 /PRNewswire/ -- Axxess, the leading global innovator for healthcare at home, announced the keynote speaker, session track topics and a new awards program for the upcoming 2024 Axxess Growth, Innovation and Leadership Experience, or AGILE. AGILE will be held April 21-24, 2024, in Dallas, Texas.

Key Points: 
  • DALLAS, Nov. 14, 2023 /PRNewswire/ -- Axxess, the leading global innovator for healthcare at home, announced the keynote speaker, session track topics and a new awards program for the upcoming 2024 Axxess Growth, Innovation and Leadership Experience, or AGILE.
  • AGILE will be held April 21-24, 2024, in Dallas, Texas.
  • AGILE will empower and excite attendees with new ways to drive growth, innovation and leadership in their organization.
  • AGILE 2024 will feature the presentation of three awards to care at home providers who excel in compliance and standards, quality of care, and overall excellence in growth and innovation.

DIRTT Selected for Major Energy Headquarter Projects in Houston

Retrieved on: 
Tuesday, October 10, 2023

CALGARY, Alberta, Oct. 10, 2023 (GLOBE NEWSWIRE) -- DIRTT and its Construction Partner AGILE INTERIORS (“AGILE”) in Houston, Texas recently secured approximately $10M USD in construction projects to build new workplaces for major energy clients Bechtel and Apache.

Key Points: 
  • CALGARY, Alberta, Oct. 10, 2023 (GLOBE NEWSWIRE) -- DIRTT and its Construction Partner AGILE INTERIORS (“AGILE”) in Houston, Texas recently secured approximately $10M USD in construction projects to build new workplaces for major energy clients Bechtel and Apache.
  • These projects were awarded due to AGILE’s proven ability to deliver class A office spaces using DIRTT’s innovative interior solutions and streamlined construction methodology.
  • Global project management, construction, and engineering firm Bechtel announced in 2022 plans to change its energy headquarters, moving its Houston-based employees to facilitate its transition to hybrid working.
  • "These projects demonstrate DIRTT’s ability to deliver adaptable solutions that prioritize the employee experience and productivity,” said Benjamin Urban, CEO of DIRTT.

Top Elevator and Escalator Companies like Otis, Schindler, and KONE, to help Propel North America Market Growth in 2023 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 14, 2023

The "North America Elevator and Escalator - Market Size & Growth Forecast 2023-2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Elevator and Escalator - Market Size & Growth Forecast 2023-2029" report has been added to ResearchAndMarkets.com's offering.
  • The North America elevator and escalator market is set to experience a steady growth trajectory, projecting a Compound Annual Growth Rate (CAGR) of 2.84% during the period of 2023-2029.
  • The trend of developing buildings with sky bridges is gaining traction in the North America elevator and escalator market.
  • The North America elevator and escalator market can be segmented based on various factors:

DIRTT Construction Partner Network Growing With New DIRTT Experience Centers

Retrieved on: 
Tuesday, May 30, 2023

Three of DIRTT’s Construction Partners, Construkt/Workscape, Intellistruct/Bialek, and AGILE INTERIORS opened the doors to their new DIRTT Experience Centers (“DXCs”), welcoming hundreds of design and construction industry professionals including general contractors, architects, and designers.

Key Points: 
  • Three of DIRTT’s Construction Partners, Construkt/Workscape, Intellistruct/Bialek, and AGILE INTERIORS opened the doors to their new DIRTT Experience Centers (“DXCs”), welcoming hundreds of design and construction industry professionals including general contractors, architects, and designers.
  • DXCs are spaces for clients and industry professionals to immerse themselves in the possibilities of building with the DIRTT Construction System.
  • DIRTT’s network of partner DXCs demonstrates how DIRTT continues to push the limits, showcasing design and innovation, form, and function.
  • Benjamin Urban, CEO, commented, “These openings demonstrate the confidence our partners have in the value the DIRTT Construction System provides to their clients.

Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma

Retrieved on: 
Wednesday, May 10, 2023

"The prognosis for patients diagnosed with acute myeloid leukemia or cholangiocarcinoma has historically been poor with very limited treatment options.

Key Points: 
  • "The prognosis for patients diagnosed with acute myeloid leukemia or cholangiocarcinoma has historically been poor with very limited treatment options.
  • With today's approval by the European Commission, Tibsovo® is now the first targeted IDH1 inhibitor approved in Europe.
  • "IDH1 mutations are major drivers of disease progression in acute myeloid leukemia and cholangiocarcinoma, which are usually diagnosed at an advanced stage, highlighting the urgent need for a targeted therapeutic option.
  • The European Commission's approval in cholangiocarcinoma is supported by data from the ClarIDHy trial, the first and only randomized Phase 3 trial for previously treated IDH1-mutated cholangiocarcinoma.

Axxess Announces 2024 AGILE Conference to be Held April 21-24

Retrieved on: 
Thursday, April 20, 2023

DALLAS, April 20, 2023 /PRNewswire/ -- Following the overwhelming success of Axxess' first-ever AGILE conference held this week, the company has already announced its 2024 conference will be held April 21-24 in Dallas.

Key Points: 
  • DALLAS, April 20, 2023 /PRNewswire/ -- Following the overwhelming success of Axxess' first-ever AGILE conference held this week, the company has already announced its 2024 conference will be held April 21-24 in Dallas.
  • "I have heard so many great comments from people on the value they got out of the conference, but I promise you next year's will be even bigger and better."
  • The AGILE conference formally began with a keynote address from Dallas Mavericks president and CEO Cynt Marshall, who spoke on the importance of leading by promoting a culture of inclusivity.
  • Along with keynote speakers, panels and industry-specific education sessions offering continuing education credits, AGILE also included an Innovation Showcase.

Servier Announces Partnership with QIAGEN to Develop New mIDH1 Companion Diagnostic Test to Support Servier's Onco-hematology Portfolio

Retrieved on: 
Thursday, March 9, 2023

This test will be for use with Servier's marketed and investigational targeted treatments in Acute Myeloid Leukemia (AML).

Key Points: 
  • This test will be for use with Servier's marketed and investigational targeted treatments in Acute Myeloid Leukemia (AML).
  • QIAGEN and Servier are collaborating to develop a PCR-based companion diagnostic test that can be used to rapidly identify AML patients with IDH1 gene mutations.
  • The companion diagnostic will run on the QIAGEN Rotor-Gene Q MDx device, which is widely used by labs worldwide.
  • QIAGEN's experienced regulatory teams will support clinical validation of the companion diagnostic and its approval in the US, the European Union and Japan.